化合物WM-1119 T4679
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
1 mL | 2055397-28-7 | ¥530.00 | 询底价 |
10 mg | 2055397-28-7 | ¥659.00 | 询底价 |
5 mg | 2055397-28-7 | ¥493.00 | 询底价 |
50 mg | 2055397-28-7 | ¥1,930.00 | 询底价 |
1 mg | 2055397-28-7 | ¥221.00 | 询底价 |
25 mg | 2055397-28-7 | ¥1,230.00 | 询底价 |
100 mg | 2055397-28-7 | ¥3,720.00 | 询底价 |
500 mg | 2055397-28-7 | ¥7,880.00 | 询底价 |
Product Introduction
Bioactivity
英文名: WM-1119
描述: WM-1119 是一种强选择性KAT6A 抑制剂,在淋巴瘤细胞中测得对 KAT6A 的IC50值为 0.25 μM,对 KAT6A,KAT5和KAT7 的结合KD 值分别为 2 nM、2.2 μM 和0.5 μM。
动物实验: Male C57BL/6-albino (B6(Cg)-Tyrc-2J/J) mice are injected intravenously with 100,000 EMRK1184 cells transfected with a luciferase-expression construct. Lymphoma growth is monitored. Three days after the lymphomacell transplant, all mice show luciferase activity, which indicate the expansion of lymphoma cells. Mice are then divided randomly into WM-1119-treatment with different conentrations (1, 2.5, 5, 10 μM) and vehicle-control groups. Because WM-1119 is rapidly cleared after intraperitoneal injection, with the plasma concentration decreasing to below 1 μM after 4-6 h cohorts of mice are injected every 8 h (three times per day, two cohorts of three mice per treatment group) or every 6 h (four times per day, two cohorts of three and six mice per treatment group).By day 14, the cohorts that are treated four times per day with WM-1119 have arrested tumour growth, with the exception of one mouse that does not respond. Spleen weights in the WM-1119-treatment group (treated four times per day) are substantially lower than spleen weights in the vehicle-treated group, and not significantly different from those of tumour-free eight-weekold mice. Treatment with WM-1119 three times per day leads to a significant reduction in tumour burden and spleen weight, but is not as effective as treatment four times per day. WM-1119 is well-tolerated; mice show no generalized ill effects and weight loss is not observed. WM-1119 treatment has no effect on haematocrit, erythrocytes or platelet numbers, but there is overall leukopenia. The proportion and overall number of tumour cells is substantially reduced by WM-1119 treatment (four times per day).
体外活性: WM-1119 induces cell cycle exit and cellular senescence without causing DNA damage. WM-1119 is 1,100-fold and 250-fold more active against KAT6A than against KAT5 or KAT7, respectively, and so shows greater specificity for KAT6A than does WM-8014. The testing of WM-1119 at 1 μM and 10 μM against a pharmacological panel of 159 diverse biological targets reveal no affinity. Treatment of MEFs with WM-1119 results in cell cycle arrest in G1 and a senescence phenotype similar to that seen upon treatment with WM-8014. Notably, the activity of WM-1119 in this cell-based assay is an order of magnitude greater than WM-8014 and WM-1119 is able to induce cell cycle arrest at 1 μM. Treatment with WM-8014 or WM-1119 inhibits the proliferation of the EMRK1184 lymphoma cells in vitro, WM-1119 (IC50=0.25 μM) is ninefold more active than WM-8014 (IC50=2.3 μM), as expected on the basis of reduced protein binding
体内活性: Male C57BL/6-albino (B6(Cg)-Tyrc-2J/J) mice are injected intravenously with 100,000 EMRK1184 cells transfected with a luciferase-expression construct. Lymphoma growth is monitored. Three days after the lymphomacell transplant, all mice show luciferase activity, which indicate the expansion of lymphoma cells. Mice are then divided randomly into WM-1119-treatment with different conentrations (1, 2.5, 5, 10 μM) and vehicle-control groups. Because WM-1119 is rapidly cleared after intraperitoneal injection, with the plasma concentration decreasing to below 1 μM after 4-6 h cohorts of mice are injected every 8 h (three times per day, two cohorts of three mice per treatment group) or every 6 h (four times per day, two cohorts of three and six mice per treatment group).By day 14, the cohorts that are treated four times per day with WM-1119 have arrested tumour growth, with the exception of one mouse that does not respond. Spleen weights in the WM-1119-treatment group (treated four times per day) are substantially lower than spleen weights in the vehicle-treated group, and not significantly different from those of tumour-free eight-weekold mice. Treatment with WM-1119 three times per day leads to a significant reduction in tumour burden and spleen weight, but is not as effective as treatment four times per day. WM-1119 is well-tolerated; mice show no generalized ill effects and weight loss is not observed. WM-1119 treatment has no effect on haematocrit, erythrocytes or platelet numbers, but there is overall leukopenia. The proportion and overall number of tumour cells is substantially reduced by WM-1119 treatment (four times per day).
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 150 mg/mL (385.23 mM)
关键字: WM 1119 | WM-1119 | Histone Acetyltransferase | HATs | HAT | Inhibitor | inhibit
相关产品: PF-CBP1 hydrochloride | CPI-637 | PU139 | MOZ-IN-2 | MOZ-IN-3 | CCT077791 | A-485 | Anacardic Acid | JG-2016 | C646
相关库: Anti-Aging Compound Library | Anti-Hypertension Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Epigenetics Compound Library | Highly Selective Inhibitor Library | Hematonosis Compound Library | Stem Cell Differentiation Compound Library | Anti-Cardiovascular Disease Compound Library | Histone Modification Compound Library
化合物WM-1119 T4679信息由TargetMol中国为您提供,如您想了解更多关于化合物WM-1119 T4679报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途